Papić, I., Bistrović, P., Krečak, I., Ortner Hadžiabdić, M. & Lucijanić, M. (2024). Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use. Journal of Psychopharmacology, /.. doi: 10.1177/02698811241237868
Papić, Ivan, et al. "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use." Journal of Psychopharmacology, vol. /, 2024. https://doi.org/10.1177/02698811241237868
Papić, Ivan, Petra Bistrović, Ivan Krečak, Maja Ortner Hadžiabdić and Marko Lucijanić. "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use." Journal of Psychopharmacology / (2024). https://doi.org/10.1177/02698811241237868
Papić, I., et al. (2024) 'Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use', Journal of Psychopharmacology, /. doi: 10.1177/02698811241237868
Papić I, Bistrović P, Krečak I, Ortner Hadžiabdić M, Lucijanić M. Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use. Journal of Psychopharmacology [Internet]. 2024 March 13 [cited 2024 September 04];/. doi: 10.1177/02698811241237868
I. Papić, P. Bistrović, I. Krečak, M. Ortner Hadžiabdić and M. Lucijanić, "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use", Journal of Psychopharmacology, vol. /, March 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:698082. [Accessed: 04 September 2024]